{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:34:45Z","timestamp":1795026885698,"version":"4.10.2"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41582-020-00427-y","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T12:16:20Z","timestamp":1605874580000},"page":"37-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":393,"title":["Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9631-7181","authenticated-orcid":false,"given":"Irene","family":"Cortese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2628-4334","authenticated-orcid":false,"given":"Daniel S.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avindra","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"427_CR1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","volume":"1","author":"BL Padgett","year":"1971","unstructured":"Padgett, B. L., Walker, D. L., ZuRhein, G. M., Eckroade, R. J. & Dessel, B. H. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1, 1257\u20131260 (1971).","journal-title":"Lancet"},{"key":"427_CR2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.meegid.2017.06.011","volume":"54","author":"U Moens","year":"2017","unstructured":"Moens, U. et al. Biology, evolution, and medical importance of polyomaviruses: an update. Infect. Genet. Evol. 54, 18\u201338 (2017).","journal-title":"Infect. Genet. Evol."},{"key":"427_CR3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003206","volume":"9","author":"MK White","year":"2013","unstructured":"White, M. K., Gordon, J. & Khalili, K. The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. PLoS Pathog. 9, e1003206 (2013).","journal-title":"PLoS Pathog."},{"key":"427_CR4","volume":"12","author":"CB Buck","year":"2016","unstructured":"Buck, C. B. et al. The ancient evolutionary history of polyomaviruses. PLoS Pathog. 12, e1005574 (2016).","journal-title":"PLoS Pathog."},{"key":"427_CR5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00239-019-09913-4","volume":"88","author":"GL Kaj\u00e1n","year":"2020","unstructured":"Kaj\u00e1n, G. L., Doszpoly, A., Tarj\u00e1n, Z. L., Vidovszky, M. Z. & Papp, T. Virus-host coevolution with a focus on animal and human DNA viruses. J. Mol. Evol. 88, 41\u201356 (2020).","journal-title":"J. Mol. Evol."},{"key":"427_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00705-003-0214-6","volume":"149","author":"H-Y Zheng","year":"2004","unstructured":"Zheng, H.-Y., Kitamura, T., Takasaka, T., Chen, Q. & Yogo, Y. Unambiguous identification of JC polyomavirus strains transmitted from parents to children. Arch. Virol. 149, 261\u2013273 (2004).","journal-title":"Arch. Virol."},{"key":"427_CR7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","volume":"71","author":"WA Knowles","year":"2003","unstructured":"Knowles, W. A. et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol. 71, 115\u2013123 (2003).","journal-title":"J. Med. Virol."},{"key":"427_CR8","volume":"5","author":"JM Kean","year":"2009","unstructured":"Kean, J. M., Rao, S., Wang, M. & Garcea, R. L. Seroepidemiology of human polyomaviruses. PLoS Pathog. 5, e1000363 (2009).","journal-title":"PLoS Pathog."},{"key":"427_CR9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","volume":"199","author":"A Egli","year":"2009","unstructured":"Egli, A. et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis. 199, 837\u2013846 (2009).","journal-title":"J. Infect. Dis."},{"key":"427_CR10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1055\/s-0036-1583609","volume":"47","author":"EM Hennes","year":"2016","unstructured":"Hennes, E. M. et al. Age-dependent seroprevalence of JCV antibody in children. Neuropediatrics 47, 112\u2013114 (2016).","journal-title":"Neuropediatrics"},{"key":"427_CR11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/rmv.1747","volume":"23","author":"U Moens","year":"2013","unstructured":"Moens, U., Van Ghelue, M., Song, X. & Ehlers, B. Serological cross-reactivity between human polyomaviruses. Rev. Med. Virol. 23, 250\u2013264 (2013).","journal-title":"Rev. Med. Virol."},{"key":"427_CR12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/13550280390195306","volume":"9","author":"S Bofill-Mas","year":"2003","unstructured":"Bofill-Mas, S. & Girones, R. Role of the environment in the transmission of JC virus. J. Neurovirol. 9, 54\u201358 (2003).","journal-title":"J. Neurovirol."},{"key":"427_CR13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/1469-0691.12538","volume":"20","author":"HH Hirsch","year":"2014","unstructured":"Hirsch, H. H. et al. European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. Clin. Microbiol. Infect. 20, 74\u201388 (2014).","journal-title":"Clin. Microbiol. Infect."},{"key":"427_CR14","doi-asserted-by":"crossref","first-page":"9918","DOI":"10.1128\/JVI.72.12.9918-9923.1998","volume":"72","author":"MC Monaco","year":"1998","unstructured":"Monaco, M. C., Jensen, P. N., Hou, J., Durham, L. C. & Major, E. O. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J. Virol. 72, 9918\u20139923 (1998).","journal-title":"J. Virol."},{"key":"427_CR15","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1128\/JVI.75.21.10290-10299.2001","volume":"75","author":"S Bofill-Mas","year":"2001","unstructured":"Bofill-Mas, S., Formiga-Cruz, M., Clemente-Casares, P., Calafell, F. & Girones, R. Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J. Virol. 75, 10290\u201310299 (2001).","journal-title":"J. Virol."},{"key":"427_CR16","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/jvi.70.10.7004-7012.1996","volume":"70","author":"MC Monaco","year":"1996","unstructured":"Monaco, M. C., Atwood, W. J., Gravell, M., Tornatore, C. S. & Major, E. O. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J. Virol. 70, 7004\u20137012 (1996).","journal-title":"J. Virol."},{"key":"427_CR17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/infdis\/jiq097","volume":"203","author":"MK White","year":"2011","unstructured":"White, M. K. & Khalili, K. Pathogenesis of progressive multifocal leukoencephalopathy\u2013revisited. J. Infect. Dis. 203, 578\u2013586 (2011).","journal-title":"J. Infect. Dis."},{"key":"427_CR18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1128\/AEM.66.1.238-245.2000","volume":"66","author":"S Bofill-Mas","year":"2000","unstructured":"Bofill-Mas, S., Pina, S. & Girones, R. Documenting the epidemiologic patterns of polyomaviruses in human populations by studying their presence in urban sewage. Appl. Env. Microbiol. 66, 238\u2013245 (2000).","journal-title":"Appl. Env. Microbiol."},{"key":"427_CR19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/jcm.35.5.1255-1257.1997","volume":"35","author":"T Kitamura","year":"1997","unstructured":"Kitamura, T. et al. Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains. J. Clin. Microbiol. 35, 1255\u20131257 (1997).","journal-title":"J. Clin. Microbiol."},{"key":"427_CR20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.24371","volume":"77","author":"HS Wollebo","year":"2015","unstructured":"Wollebo, H. S., White, M. K., Gordon, J., Berger, J. R. & Khalili, K. Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann. Neurol. 77, 560\u2013570 (2015).","journal-title":"Ann. Neurol."},{"key":"427_CR21","first-page":"179","volume":"41","author":"V Pietropaolo","year":"2018","unstructured":"Pietropaolo, V., Prezioso, C., Bagnato, F. & Antonelli, G. John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy. New Microbiol. 41, 179\u2013186 (2018).","journal-title":"New Microbiol."},{"key":"427_CR22","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/344280","volume":"186","author":"BF Sabath","year":"2002","unstructured":"Sabath, B. F. & Major, E. O. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J. Infect. Dis. 186, S180\u2013S186 (2002).","journal-title":"J. Infect. Dis."},{"key":"427_CR23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11481-010-9203-1","volume":"5","author":"LJ Marshall","year":"2010","unstructured":"Marshall, L. J. & Major, E. O. Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy. J. Neuroimmune Pharmacol. 5, 404\u2013417 (2010).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"427_CR24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","volume":"25","author":"MW Ferenczy","year":"2012","unstructured":"Ferenczy, M. W. et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin. Microbiol. Rev. 25, 471\u2013506 (2012).","journal-title":"Clin. Microbiol. Rev."},{"key":"427_CR25","doi-asserted-by":"crossref","first-page":"9687","DOI":"10.1128\/JVI.75.20.9687-9695.2001","volume":"75","author":"MC Monaco","year":"2001","unstructured":"Monaco, M. C., Sabath, B. F., Durham, L. C. & Major, E. O. JC virus multiplication in human hematopoietic progenitor cells requires the NF-1 class D transcription factor. J. Virol. 75, 9687\u20139695 (2001).","journal-title":"J. Virol."},{"key":"427_CR26","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1128\/jvi.64.6.3139-3143.1990","volume":"64","author":"Y Yogo","year":"1990","unstructured":"Yogo, Y. et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J. Virol. 64, 3139\u20133143 (1990).","journal-title":"J. Virol."},{"key":"427_CR27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/viro.1996.0037","volume":"216","author":"AM Daniel","year":"1996","unstructured":"Daniel, A. M., Swenson, J. J., Mayreddy, R. P., Khalili, K. & Frisque, R. J. Sequences within the early and late promoters of archetype JC virus restrict viral DNA replication and infectivity. Virology 216, 90\u2013101 (1996).","journal-title":"Virology"},{"key":"427_CR28","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1128\/JVI.02565-14","volume":"89","author":"T Van Loy","year":"2015","unstructured":"Van Loy, T. et al. JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route. J. Virol. 89, 1340\u20131347 (2015).","journal-title":"J. Virol."},{"key":"427_CR29","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1099\/0022-1317-82-5-1221","volume":"82","author":"HT Agostini","year":"2001","unstructured":"Agostini, H. T. et al. Genotypes of JC virus in east, central and southwest Europe. J. Gen. Virol. 82, 1221\u20131331 (2001).","journal-title":"J. Gen. Virol."},{"key":"427_CR30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1099\/0022-1317-74-8-1499","volume":"74","author":"GS Ault","year":"1993","unstructured":"Ault, G. S. & Stoner, G. L. Human polyomavirus JC promoter\/enhancer rearrangement patterns from progressive multifocal leukoencephalopathy brain are unique derivatives of a single archetypal structure. J. Gen. Virol. 74, 1499\u20131507 (1993).","journal-title":"J. Gen. Virol."},{"key":"427_CR31","doi-asserted-by":"crossref","first-page":"10448","DOI":"10.1128\/JVI.00614-10","volume":"84","author":"R Gosert","year":"2010","unstructured":"Gosert, R., Kardas, P., Major, E. O. & Hirsch, H. H. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J. Virol. 84, 10448\u201310456 (2010).","journal-title":"J. Virol."},{"key":"427_CR32","doi-asserted-by":"crossref","first-page":"197807","DOI":"10.1155\/2013\/197807","volume":"2013","author":"EM Johnson","year":"2013","unstructured":"Johnson, E. M. et al. in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy. Clin. Dev. Immunol. 2013, 197807\u2013197810 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"427_CR33","volume":"13","author":"A-S L\u2019Honneur","year":"2018","unstructured":"L\u2019Honneur, A.-S. et al. Exploring the role of NCCR variation on JC polyomavirus expression from dual reporter minicircles. PLoS One 13, e0199171 (2018).","journal-title":"PLoS One"},{"key":"427_CR34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00705-012-1532-3","volume":"158","author":"K Nakamichi","year":"2013","unstructured":"Nakamichi, K. et al. Sequential changes in the non-coding control region sequences of JC polyomaviruses from the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. Arch. Virol. 158, 639\u2013650 (2013).","journal-title":"Arch. Virol."},{"key":"427_CR35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/jnnp.71.3.397","volume":"71","author":"Y Yogo","year":"2001","unstructured":"Yogo, Y. et al. JC virus regulatory region rearrangements in the brain of a long surviving patient with progressive multifocal leukoencephalopathy. J. Neurol. Neurosurg. Psychiatry 71, 397\u2013400 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"427_CR36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1212\/01.WNL.0000096147.47128.7D","volume":"61","author":"Y Yasuda","year":"2003","unstructured":"Yasuda, Y. et al. Comparison of PCR-amplified JC virus control region sequences from multiple brain regions in PML. Neurology 61, 1617\u20131619 (2003).","journal-title":"Neurology"},{"key":"427_CR37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jmv.1890470306","volume":"47","author":"P Ferrante","year":"1995","unstructured":"Ferrante, P. et al. PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy. J. Med. Virol. 47, 219\u2013225 (1995).","journal-title":"J. Med. Virol."},{"key":"427_CR38","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/jmv.21313","volume":"80","author":"S Delbue","year":"2008","unstructured":"Delbue, S. et al. Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals. J. Med. Virol. 80, 2147\u20132152 (2008).","journal-title":"J. Med. Virol."},{"key":"427_CR39","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/jvi.66.10.5726-5734.1992","volume":"66","author":"FA White","year":"1992","unstructured":"White, F. A., Ishaq, M., Stoner, G. L. & Frisque, R. J. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J. Virol. 66, 5726\u20135734 (1992).","journal-title":"J. Virol."},{"key":"427_CR40","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1128\/JVI.00609-10","volume":"84","author":"CS Tan","year":"2010","unstructured":"Tan, C. S. et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J. Virol. 84, 9200\u20139209 (2010).","journal-title":"J. Virol."},{"key":"427_CR41","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.24148","volume":"75","author":"S Chalkias","year":"2014","unstructured":"Chalkias, S. et al. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann. Neurol. 75, 925\u2013934 (2014).","journal-title":"Ann. Neurol."},{"key":"427_CR42","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1128\/jcm.35.9.2288-2292.1997","volume":"35","author":"V Dubois","year":"1997","unstructured":"Dubois, V. et al. Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J. Clin. Microbiol. 35, 2288\u20132292 (1997).","journal-title":"J. Clin. Microbiol."},{"key":"427_CR43","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","volume":"127","author":"DuRA Pasquier","year":"2004","unstructured":"Pasquier, Du. R. A. et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127, 1970\u20131978 (2004).","journal-title":"Brain"},{"key":"427_CR44","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1128\/JVI.02506-10","volume":"85","author":"S Gheuens","year":"2011","unstructured":"Gheuens, S. et al. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J. Virol. 85, 7256\u20137263 (2011).","journal-title":"J. Virol."},{"key":"427_CR45","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1128\/JVI.02657-08","volume":"83","author":"N Khanna","year":"2009","unstructured":"Khanna, N., Wolbers, M., Mueller, N. J., Garzoni, C., Pasquier, Du. R. A. & Fux, C. A. et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J. Virol. 83, 4404\u20134411 (2009).","journal-title":"J. Virol."},{"key":"427_CR46","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.bbmt.2014.03.018","volume":"20","author":"CS Tan","year":"2014","unstructured":"Tan, C. S. et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation. Biol. Blood Marrow Transpl. 20, 992\u2013999 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"427_CR47","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/bmt.2015.68","volume":"50","author":"T Wittmann","year":"2015","unstructured":"Wittmann, T. et al. JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications. Bone Marrow Transpl. 50, 984\u2013991 (2015).","journal-title":"Bone Marrow Transpl."},{"key":"427_CR48","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","volume":"361","author":"Y Chen","year":"2009","unstructured":"Chen, Y. et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361, 1067\u20131074 (2009).","journal-title":"N. Engl. J. Med."},{"key":"427_CR49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s13365-015-0338-y","volume":"21","author":"V Pietropaolo","year":"2015","unstructured":"Pietropaolo, V. et al. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment. J. Neurovirol. 21, 653\u2013665 (2015).","journal-title":"J. Neurovirol."},{"key":"427_CR50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13365-011-0036-3","volume":"17","author":"A Bellizzi","year":"2011","unstructured":"Bellizzi, A. et al. Polyomavirus JC reactivation and noncoding control region sequence analysis in pediatric Crohn\u2019s disease patients treated with infliximab. J. Neurovirol 17, 303\u2013313 (2011).","journal-title":"J. Neurovirol"},{"key":"427_CR51","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1099\/vir.0.80863-0","volume":"86","author":"H-Y Zheng","year":"2005","unstructured":"Zheng, H.-Y. et al. New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy. J. Gen. Virol. 86, 2035\u20132045 (2005).","journal-title":"J. Gen. Virol."},{"key":"427_CR52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13550280802425467","volume":"15","author":"S Delbue","year":"2009","unstructured":"Delbue, S. et al. JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy. J. Neurovirol 15, 51\u201356 (2009).","journal-title":"J. Neurovirol"},{"key":"427_CR53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000368","volume":"5","author":"SR Sunyaev","year":"2009","unstructured":"Sunyaev, S. R., Lugovskoy, A., Simon, K. & Gorelik, L. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 5, e1000368 (2009).","journal-title":"PLoS Genet."},{"key":"427_CR54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/jir198","volume":"204","author":"L Gorelik","year":"2011","unstructured":"Gorelik, L. et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J. Infect. Dis. 204, 103\u2013114 (2011).","journal-title":"J. Infect. Dis."},{"key":"427_CR55","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/JVI.02803-12","volume":"87","author":"I Jelcic","year":"2013","unstructured":"Jelcic, I. et al. T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J. Virol. 87, 3393\u20133408 (2013).","journal-title":"J. Virol."},{"key":"427_CR56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.54.3.743","volume":"54","author":"C Power","year":"2000","unstructured":"Power, C. et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 54, 743\u2013746 (2000).","journal-title":"Neurology"},{"key":"427_CR57","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fneur.2020.00186","volume":"11","author":"PS Eis","year":"2020","unstructured":"Eis, P. S. et al. Germline genetic risk variants for progressive multifocal leukoencephalopathy. Front. Neurol. 11, 186 (2020).","journal-title":"Front. Neurol."},{"key":"427_CR58","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1073\/pnas.87.9.3479","volume":"87","author":"H Tada","year":"1990","unstructured":"Tada, H. et al. Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc. Natl Acad. Sci. USA 87, 3479\u20133483 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"427_CR59","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1089\/dna.2004.23.858","volume":"23","author":"DC Daniel","year":"2004","unstructured":"Daniel, D. C. et al. Internalization of exogenous human immunodeficiency virus-1 protein, Tat, by KG-1 oligodendroglioma cells followed by stimulation of DNA replication initiated at the JC virus origin. DNA Cell Biol. 23, 858\u2013867 (2004).","journal-title":"DNA Cell Biol."},{"key":"427_CR60","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1099\/vir.0.023184-0","volume":"91","author":"LJ Marshall","year":"2010","unstructured":"Marshall, L. J., Dunham, L. & Major, E. O. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter\/enhancer of JC virus and supports viral activity. J. Gen. Virol. 91, 3042\u20133052 (2010).","journal-title":"J. Gen. Virol."},{"key":"427_CR61","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1128\/JVI.03221-13","volume":"88","author":"LJ Marshall","year":"2014","unstructured":"Marshall, L. J. et al. Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. J. Virol. 88, 5177\u20135183 (2014).","journal-title":"J. Virol."},{"key":"427_CR62","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","volume":"71","author":"EM Frohman","year":"2014","unstructured":"Frohman, E. M. et al. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol. 71, 596\u2013602 (2014).","journal-title":"JAMA Neurol."},{"key":"427_CR63","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.imbio.2018.01.002","volume":"223","author":"D Pavlovic","year":"2018","unstructured":"Pavlovic, D., Patel, M. A., Patera, A. C. & Peterson, I., Progressive Multifocal Leukoencephalopathy Consortium. T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. Immunobiology 223, 508\u2013517 (2018).","journal-title":"Immunobiology"},{"key":"427_CR64","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger, J. R. et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80, 1430\u20131438 (2013).","journal-title":"Neurology"},{"key":"427_CR65","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.22137","volume":"68","author":"CF Ryschkewitsch","year":"2010","unstructured":"Ryschkewitsch, C. F., Jensen, P. N., Monaco, M. C. & Major, E. O. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 68, 384\u2013391 (2010).","journal-title":"Ann. Neurol."},{"key":"427_CR66","first-page":"232470961773424","volume":"5","author":"M Himedan","year":"2017","unstructured":"Himedan, M. et al. Pathologic findings of chronic PML-IRIS in a patient with prolonged PML survival following natalizumab treatment. J. Investig. Med. High Impact Case Rep. 5, 2324709617734248 (2017).","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"427_CR67","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s13365-015-0419-y","volume":"22","author":"KM Crossley","year":"2016","unstructured":"Crossley, K. M. et al. Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals. J. Neurovirol. 22, 541\u2013545 (2016).","journal-title":"J. Neurovirol."},{"key":"427_CR68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/81.1.93","volume":"81","author":"KE Astrom","year":"1958","unstructured":"Astrom, K. E., Mancall, E. L. & Richardson, E. P. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin\u2019s disease. Brain 81, 93\u2013111 (1958).","journal-title":"Brain"},{"key":"427_CR69","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","volume":"2","author":"BR Brooks","year":"1984","unstructured":"Brooks, B. R. & Walker, D. L. Progressive multifocal leukoencephalopathy. Neurol. Clin. 2, 299\u2013313 (1984).","journal-title":"Neurol. Clin."},{"key":"427_CR70","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","volume":"120","author":"KR Carson","year":"2014","unstructured":"Carson, K. R. et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120, 2464\u20132471 (2014).","journal-title":"Cancer"},{"key":"427_CR71","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","volume":"8","author":"D Pavlovic","year":"2015","unstructured":"Pavlovic, D., Patera, A. C., Nyberg, F., Gerber, M. & Liu, M. Progressive multifocal leukeoncephalopathy consortium. progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther. Adv. Neurol. Disord. 8, 255\u2013273 (2015).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"427_CR72","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2169\/internalmedicine.54.2308","volume":"54","author":"Y Sano","year":"2015","unstructured":"Sano, Y. et al. Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment. Intern. Med. 54, 965\u2013970 (2015).","journal-title":"Intern. Med."},{"key":"427_CR73","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJM198212023072307","volume":"307","author":"JR Miller","year":"1982","unstructured":"Miller, J. R. et al. Progressive multifocal leukoencaphalopathy in a male homosexual with T-cell immune deficiency. N. Engl. J. Med. 307, 1436\u20131438 (1982).","journal-title":"N. Engl. J. Med."},{"key":"427_CR74","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000311014","volume":"35","author":"KLY Christensen","year":"2010","unstructured":"Christensen, K. L. Y., Holman, R. C., Hammett, T. A., Belay, E. D. & Schonberger, L. B. Progressive multifocal leukoencephalopathy deaths in the USA, 1979\u20132005. Neuroepidemiology 35, 178\u2013184 (2010).","journal-title":"Neuroepidemiology"},{"key":"427_CR75","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","volume":"4","author":"JR Berger","year":"1998","unstructured":"Berger, J. R., Pall, L., Lanska, D. & Whiteman, M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J. Neurovirol. 4, 59\u201368 (1998).","journal-title":"J. Neurovirol."},{"key":"427_CR76","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/13550280701469178","volume":"13","author":"F Bernal-Cano","year":"2007","unstructured":"Bernal-Cano, F., Joseph, J. T. & Koralnik, I. J. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J. Neurovirol. 13, 474\u2013476 (2007).","journal-title":"J. Neurovirol."},{"key":"427_CR77","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1440-1789.2008.00981.x","volume":"29","author":"S Takeda","year":"2009","unstructured":"Takeda, S. et al. Progressive multifocal leukoencephalopathy showing extensive spinal cord involvement in a patient with lymphocytopenia. Neuropathology 29, 485\u2013493 (2009).","journal-title":"Neuropathology"},{"key":"427_CR78","doi-asserted-by":"crossref","first-page":"566-e41","DOI":"10.1111\/ene.13906","volume":"26","author":"T Bartsch","year":"2019","unstructured":"Bartsch, T. et al. The spectrum of progressive multifocal leukoencephalopathy: a practical approach. Eur. J. Neurol. 26, 566-e41 (2019).","journal-title":"Eur. J. Neurol."},{"key":"427_CR79","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s13365-015-0414-3","volume":"22","author":"DP Miskin","year":"2016","unstructured":"Miskin, D. P., Herman, S. T., Ngo, L. H. & Koralnik, I. J. Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy. J. Neurovirol. 22, 464\u2013471 (2016).","journal-title":"J. Neurovirol."},{"key":"427_CR80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/NEN.0b013e31823ede59","volume":"71","author":"C Wuthrich","year":"2012","unstructured":"Wuthrich, C. & Koralnik, I. J. Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J. Neuropathol. Exp. Neurol. 71, 54\u201365 (2012).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"427_CR81","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/neup.12562","volume":"39","author":"D Ono","year":"2019","unstructured":"Ono, D. et al. Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): comparison of magnetic resonance images and neuropathology of post-mortem brain. Neuropathology 39, 294\u2013306 (2019).","journal-title":"Neuropathology"},{"key":"427_CR82","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1148\/radiology.187.1.8451420","volume":"187","author":"ML Whiteman","year":"1993","unstructured":"Whiteman, M. L. et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 187, 233\u2013240 (1993).","journal-title":"Radiology"},{"key":"427_CR83","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00234-003-1115-9","volume":"46","author":"M Bergui","year":"2004","unstructured":"Bergui, M. et al. Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. Neuroradiology 46, 22\u201325 (2004).","journal-title":"Neuroradiology"},{"key":"427_CR84","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jns.2014.06.018","volume":"344","author":"M Miyagawa","year":"2014","unstructured":"Miyagawa, M. et al. Low signal intensity in U-fiber identified by susceptibility-weighted imaging in two cases of progressive multifocal leukoencephalopathy. J. Neurol. Sci. 344, 198\u2013202 (2014).","journal-title":"J. Neurol. Sci."},{"key":"427_CR85","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3174\/ajnr.A6072","volume":"40","author":"MM Thurnher","year":"2019","unstructured":"Thurnher, M. M., Boban, J., Rieger, A. & Gelpi, E. Susceptibility-weighted MR imaging hypointense rim in progressive multifocal leukoencephalopathy: the end point of neuroinflammation and a potential outcome predictor. Am. J. Neuroradiol. 40, 994\u20131000 (2019).","journal-title":"Am. J. Neuroradiol."},{"key":"427_CR86","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fimmu.2017.00577","volume":"8","author":"A Fournier","year":"2017","unstructured":"Fournier, A. et al. Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review. Front. Immunol. 8, 577 (2017).","journal-title":"Front. Immunol."},{"key":"427_CR87","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","volume":"76","author":"C Warnke","year":"2014","unstructured":"Warnke, C. et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 792\u2013801 (2014).","journal-title":"Ann. Neurol."},{"key":"427_CR88","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0171-2985(00)80065-0","volume":"202","author":"GM Behrens","year":"2000","unstructured":"Behrens, G. M., Meyer, D., Stoll, M. & Schmidt, R. E. Immune reconstitution syndromes in human immuno-deficiency virus infection following effective antiretroviral therapy. Immunobiology 202, 186\u2013193 (2000).","journal-title":"Immunobiology"},{"key":"427_CR89","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00005792-200205000-00005","volume":"81","author":"SA Shelburne","year":"2002","unstructured":"Shelburne, S. A. et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 81, 213\u2013227 (2002).","journal-title":"Medicine"},{"key":"427_CR90","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1086\/595299","volume":"199","author":"FN Engsig","year":"2009","unstructured":"Engsig, F. N. et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J. Infect. Dis. 199, 77\u201383 (2009).","journal-title":"J. Infect. Dis."},{"key":"427_CR91","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/QAI.0b013e31817bec64","volume":"49","author":"V Falc\u00f3","year":"2008","unstructured":"Falc\u00f3, V. et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J. Acquir. Immune Defic. Syndr. 49, 26\u201331 (2008).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"427_CR92","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1089\/aid.2018.0232","volume":"35","author":"NA Summers","year":"2019","unstructured":"Summers, N. A., Kelley, C. F., Armstrong, W., Marconi, V. C. & Nguyen, M. L. Not a disease of the past: a case series of progressive multifocal leukoencephalopathy in the established antiretroviral Era. AIDS Res. Hum. Retroviruses 35, 544\u2013552 (2019).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"427_CR93","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","volume":"10","author":"M M\u00fcller","year":"2010","unstructured":"M\u00fcller, M. et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis. 10, 251\u2013261 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"427_CR94","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00401-005-0983-y","volume":"109","author":"A Vendrely","year":"2005","unstructured":"Vendrely, A. et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol. 109, 449\u2013455 (2005).","journal-title":"Acta Neuropathol."},{"key":"427_CR95","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3174\/ajnr.A3183","volume":"34","author":"MJD Post","year":"2013","unstructured":"Post, M. J. D. et al. CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome. Am. J. Neuroradiol. 34, 1297\u20131307 (2013).","journal-title":"Am. J. Neuroradiol."},{"key":"427_CR96","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/ene.12963","volume":"23","author":"S Sainz-de-la-Maza","year":"2016","unstructured":"Sainz-de-la-Maza, S. et al. Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy. Eur. J. Neurol. 23, 919\u2013925 (2016).","journal-title":"Eur. J. Neurol."},{"key":"427_CR97","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ana.410440309","volume":"44","author":"JR Berger","year":"1998","unstructured":"Berger, J. R., Levy, R. M., Flomenhoft, D. & Dobbs, M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 44, 341\u2013349 (1998).","journal-title":"Ann. Neurol."},{"key":"427_CR98","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","volume":"72","author":"K Tan","year":"2009","unstructured":"Tan, K., Roda, R., Ostrow, L., McArthur, J. & Nath, A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72, 1458\u20131464 (2009).","journal-title":"Neurology"},{"key":"427_CR99","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","volume":"77","author":"IL Tan","year":"2011","unstructured":"Tan, I. L., McArthur, J. C., Clifford, D. B., Major, E. O. & Nath, A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77, 1061\u20131067 (2011).","journal-title":"Neurology"},{"key":"427_CR100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ana.21085","volume":"62","author":"D Huang","year":"2007","unstructured":"Huang, D. et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann. Neurol. 62, 34\u201339 (2007).","journal-title":"Ann. Neurol."},{"key":"427_CR101","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e318268465b","volume":"79","author":"S Gheuens","year":"2012","unstructured":"Gheuens, S. et al. Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology 79, 1041\u20131048 (2012).","journal-title":"Neurology"},{"key":"427_CR102","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1093\/brain\/awt268","volume":"136","author":"MS Khoury","year":"2013","unstructured":"Khoury, M. S. et al. Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome. Brain 136, 3441\u20133450 (2013).","journal-title":"Brain"},{"key":"427_CR103","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1212\/WNL.0000000000006213","volume":"91","author":"A Baheerathan","year":"2018","unstructured":"Baheerathan, A. et al. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab. Neurology 91, 572\u2013573 (2018).","journal-title":"Neurology"},{"key":"427_CR104","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00401-015-1471-7","volume":"130","author":"J Bauer","year":"2015","unstructured":"Bauer, J., Gold, R., Adams, O. & Lassmann, H. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). Acta Neuropathol. 130, 751\u2013764 (2015).","journal-title":"Acta Neuropathol."},{"key":"427_CR105","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1212\/WNL.0b013e3182a43e6d","volume":"81","author":"G Martin-Blondel","year":"2013","unstructured":"Martin-Blondel, G. et al. In situ evidence of JC virus control by CD8T cells in PML-IRIS during HIV infection. Neurology 81, 964\u2013970 (2013).","journal-title":"Neurology"},{"key":"427_CR106","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","volume":"24","author":"JR Berger","year":"2018","unstructured":"Berger, J. R., Malik, V., Lacey, S., Brunetta, P. & Lehane, P. B. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J. Neurovirol. 24, 323\u2013331 (2018).","journal-title":"J. Neurovirol."},{"key":"427_CR107","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","volume":"15","author":"DW Raisch","year":"2016","unstructured":"Raisch, D. W., Rafi, J. A., Chen, C. & Bennett, C. L. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system. Expert Opin. Drug Saf. 15, 1003\u20131011 (2016).","journal-title":"Expert Opin. Drug Saf."},{"key":"427_CR108","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"16","author":"P-R Ho","year":"2017","unstructured":"Ho, P.-R. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 16, 925\u2013933 (2017).","journal-title":"Lancet Neurol."},{"key":"427_CR109","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","volume":"30","author":"EJ Boren","year":"2008","unstructured":"Boren, E. J., Cheema, G. S., Naguwa, S. M., Ansari, A. A. & Gershwin, M. E. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J. Autoimmun. 30, 90\u201398 (2008).","journal-title":"J. Autoimmun."},{"key":"427_CR110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/jnnp-2018-318261","volume":"90","author":"MT Wijburg","year":"2019","unstructured":"Wijburg, M. T. et al. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. J. Neurol. Neurosurg. Psychiatry 90, 44\u201346 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"427_CR111","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford, D. B. et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9, 438\u2013446 (2010).","journal-title":"Lancet Neurol."},{"key":"427_CR112","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","volume":"72","author":"TA Yousry","year":"2012","unstructured":"Yousry, T. A. et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 72, 779\u2013787 (2012).","journal-title":"Ann. Neurol."},{"key":"427_CR113","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1177\/1352458513510224","volume":"19","author":"MP Wattjes","year":"2013","unstructured":"Wattjes, M. P. et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult. Scler. 19, 1826\u20131840 (2013).","journal-title":"Mult. Scler."},{"key":"427_CR114","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WCO.0000000000000099","volume":"27","author":"MP Wattjes","year":"2014","unstructured":"Wattjes, M. P. & Barkhof, F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr. Opin. Neurol. 27, 260\u2013270 (2014).","journal-title":"Curr. Opin. Neurol."},{"key":"427_CR115","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/jnnp-2015-311411","volume":"87","author":"MP Wattjes","year":"2016","unstructured":"Wattjes, M. P. et al. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. J. Neurol. Neurosurg. Psychiatry 87, 879\u2013884 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"427_CR116","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870\u20131880 (2012).","journal-title":"N. Engl. J. Med."},{"key":"427_CR117","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s13365-016-0482-z","volume":"22","author":"D Campagnolo","year":"2016","unstructured":"Campagnolo, D. et al. Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV\u00ae DxSelect\u2122 antibody assay. J. Neurovirol. 22, 880\u2013881 (2016).","journal-title":"J. Neurovirol."},{"key":"427_CR118","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina, T. et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 802\u2013812 (2014).","journal-title":"Ann. Neurol."},{"key":"427_CR119","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","volume":"93","author":"LZ Ryerson","year":"2019","unstructured":"Ryerson, L. Z. et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93, e1452\u2013e1462 (2019).","journal-title":"Neurology"},{"key":"427_CR120","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1212\/WNL.0b013e31826846b4","volume":"79","author":"R Phan-Ba","year":"2012","unstructured":"Phan-Ba, R. et al. The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas? Neurology 79, 1067\u20131069 (2012).","journal-title":"Neurology"},{"key":"427_CR121","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00415-013-7191-9","volume":"261","author":"J Havla","year":"2014","unstructured":"Havla, J., Hohlfeld, R. & K\u00fcmpfel, T. Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem. J. Neurol. 261, 232\u2013234 (2014).","journal-title":"J. Neurol."},{"key":"427_CR122","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.0b013e318246d6d8","volume":"78","author":"NF Blair","year":"2012","unstructured":"Blair, N. F., Brew, B. J. & Halpern, J.-P. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology 78, 507\u2013508 (2012).","journal-title":"Neurology"},{"key":"427_CR123","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp-2011-300511","volume":"83","author":"R Phan-Ba","year":"2012","unstructured":"Phan-Ba, R. et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J. Neurol. Neurosurg. Psychiatry 83, 224\u2013226 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"427_CR124","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e31820b7644","volume":"76","author":"A Vennegoor","year":"2011","unstructured":"Vennegoor, A. et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 76, 574\u2013576 (2011).","journal-title":"Neurology"},{"key":"427_CR125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/infdis\/jis668","volume":"207","author":"J Bayliss","year":"2013","unstructured":"Bayliss, J., Karasoulos, T. & McLean, C. A. Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy. J. Infect. Dis. 207, 133\u2013136 (2013).","journal-title":"J. Infect. Dis."},{"key":"427_CR126","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jnnp-2014-308630","volume":"86","author":"MP Wattjes","year":"2015","unstructured":"Wattjes, M. P. et al. MRI pattern in asymptomatic natalizumab-associated PML. J. Neurol. Neurosurg. Psychiatry 86, 793\u2013798 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"427_CR127","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","volume":"1","author":"T Dong-Si","year":"2014","unstructured":"Dong-Si, T. et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann. Clin. Transl. Neurol. 1, 755\u2013764 (2014).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"427_CR128","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaneurol.2018.0094","volume":"75","author":"MT Wijburg","year":"2018","unstructured":"Wijburg, M. T. et al. Association of progressive multifocal leukoencephalopathy lesion volume with JC virus polymerase chain reaction results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. JAMA Neurol. 75, 827\u2013833 (2018).","journal-title":"JAMA Neurol."},{"key":"427_CR129","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00415-014-7336-5","volume":"261","author":"MP Wattjes","year":"2014","unstructured":"Wattjes, M. P. et al. Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? J. Neurol. 261, 1139\u20131143 (2014).","journal-title":"J. Neurol."},{"key":"427_CR130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/jnnp-2016-315106.113","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan, C. et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J. Neurol. Neurosurg. Psychiatry 87, 117\u2013125 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"427_CR131","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1212\/01.WNL.0000081306.86961.33","volume":"61","author":"RA Du Pasquier","year":"2003","unstructured":"Du Pasquier, R. A. et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 61, 775\u2013782 (2003).","journal-title":"Neurology"},{"key":"427_CR132","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/NEN.0b013e3181912570","volume":"68","author":"C Wuthrich","year":"2009","unstructured":"Wuthrich, C. et al. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J. Neuropathol. Exp. Neurol. 68, 15\u201325 (2009).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"427_CR133","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00415-014-7530-5","volume":"262","author":"MT Wijburg","year":"2015","unstructured":"Wijburg, M. T. et al. Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature. J. Neurol. 262, 65\u201373 (2015).","journal-title":"J. Neurol."},{"key":"427_CR134","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00415-015-8001-3","volume":"263","author":"MT Wijburg","year":"2016","unstructured":"Wijburg, M. T., Siepman, D., van Eijk, J. J. J., Killestein, J. & Wattjes, M. P. Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. J. Neurol. 263, 649\u2013656 (2016).","journal-title":"J. Neurol."},{"key":"427_CR135","first-page":"191","volume":"105","author":"EP Richardson","year":"1983","unstructured":"Richardson, E. P. & Webster, H. D. Progressive multifocal leukoencephalopathy: its pathological features. Prog. Clin. Biol. Res. 105, 191\u2013203 (1983).","journal-title":"Prog. Clin. Biol. Res."},{"key":"427_CR136","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1099\/vir.0.81945-0","volume":"87","author":"X Dang","year":"2006","unstructured":"Dang, X. & Koralnik, I. J. A granule cell neuron-associated JC virus variant has a unique deletion in the VP1 gene. J. Gen. Virol. 87, 2533\u20132537 (2006).","journal-title":"J. Gen. Virol."},{"key":"427_CR137","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1099\/vir.0.037440-0","volume":"93","author":"X Dang","year":"2012","unstructured":"Dang, X. et al. JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J. Gen. Virol. 93, 175\u2013183 (2012).","journal-title":"J. Gen. Virol."},{"key":"427_CR138","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ana.20431","volume":"57","author":"IJ Koralnik","year":"2005","unstructured":"Koralnik, I. J. et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann. Neurol. 57, 576\u2013580 (2005).","journal-title":"Ann. Neurol."},{"key":"427_CR139","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.21619","volume":"65","author":"C Wuthrich","year":"2009","unstructured":"Wuthrich, C. et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann. Neurol. 65, 742\u2013748 (2009).","journal-title":"Ann. Neurol."},{"key":"427_CR140","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/ana.25608","volume":"86","author":"LB Reoma","year":"2019","unstructured":"Reoma, L. B. et al. Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy. Ann. Neurol. 86, 878\u2013884 (2019).","journal-title":"Ann. Neurol."},{"key":"427_CR141","volume":"7","author":"X Dang","year":"2012","unstructured":"Dang, X., Wuthrich, C., Gordon, J., Sawa, H. & Koralnik, I. J. JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant. PLoS One 7, e35793 (2012).","journal-title":"PLoS One"},{"key":"427_CR142","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/adc.67.7.956","volume":"67","author":"K Blake","year":"1992","unstructured":"Blake, K. et al. JC virus associated meningoencephalitis in an immunocompetent girl. Arch. Dis. Child. 67, 956\u2013957 (1992).","journal-title":"Arch. Dis. Child."},{"key":"427_CR143","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s15010-003-3078-5","volume":"31","author":"A Behzad-Behbahani","year":"2003","unstructured":"Behzad-Behbahani, A., Klapper, P. E., Vallely, P. J., Cleator, G. M. & Bonington, A. BKV-DNA and JCV-DNA in CSF of patients with suspected meningitis or encephalitis. Infection 31, 374\u2013378 (2003).","journal-title":"Infection"},{"key":"427_CR144","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1191\/0961203305lu2229cr","volume":"14","author":"J-F Viallard","year":"2005","unstructured":"Viallard, J.-F., Ellie, E., Lazaro, E., Lafon, M.-E. & Pellegrin, J.-L. JC virus meningitis in a patient with systemic lupus erythematosus. Lupus 14, 964\u2013966 (2005).","journal-title":"Lupus"},{"key":"427_CR145","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.24192","volume":"76","author":"SP Agnihotri","year":"2014","unstructured":"Agnihotri, S. P. et al. A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient. Ann. Neurol. 76, 140\u2013147 (2014).","journal-title":"Ann. Neurol."},{"key":"427_CR146","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s13365-019-00753-y","volume":"25","author":"SM Corbridge","year":"2019","unstructured":"Corbridge, S. M. et al. JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy. J. Neurovirol. 25, 520\u2013524 (2019).","journal-title":"J. Neurovirol."},{"key":"427_CR147","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/NEN.0000000000000218","volume":"74","author":"C Wuthrich","year":"2015","unstructured":"Wuthrich, C., Batson, S. & Koralnik, I. J. Lack of major histocompatibility complex class I upregulation and restrictive infection by JC virus hamper detection of neurons by T lymphocytes in the central nervous system. J. Neuropathol. Exp. Neurol. 74, 791\u2013803 (2015).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"427_CR148","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","volume":"338","author":"CD Hall","year":"1998","unstructured":"Hall, C. D. et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N. Engl. J. Med. 338, 1345\u20131351 (1998).","journal-title":"N. Engl. J. Med."},{"key":"427_CR149","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/713831540","volume":"9","author":"W Royal","year":"2003","unstructured":"Royal, W. et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J. Neurovirol. 9, 411\u2013419 (2003).","journal-title":"J. Neurovirol."},{"key":"427_CR150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020967","volume":"6","author":"J Gasnault","year":"2011","unstructured":"Gasnault, J. et al. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6, e20967 (2011).","journal-title":"PLoS One"},{"key":"427_CR151","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","volume":"19","author":"DB Clifford","year":"2013","unstructured":"Clifford, D. B. et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J. Neurovirol. 19, 351\u2013358 (2013).","journal-title":"J. Neurovirol."},{"key":"427_CR152","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/QAD.0b013e32830a5043","volume":"22","author":"A De Luca","year":"2008","unstructured":"De Luca, A. et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 22, 1759\u20131767 (2008).","journal-title":"AIDS"},{"key":"427_CR153","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40261-016-0433-8","volume":"36","author":"Y Jamilloux","year":"2016","unstructured":"Jamilloux, Y. et al. Treatment of progressive multifocal leukoencephalopathy with mirtazapine. Clin. Drug Investig. 36, 783\u2013789 (2016).","journal-title":"Clin. Drug Investig."},{"key":"427_CR154","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/WNL.0000000000003740","volume":"88","author":"D Landi","year":"2017","unstructured":"Landi, D. et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88, 1144\u20131152 (2017).","journal-title":"Neurology"},{"key":"427_CR155","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ana.25070","volume":"82","author":"C Scarpazza","year":"2017","unstructured":"Scarpazza, C. et al. To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. Ann. Neurol. 82, 697\u2013705 (2017).","journal-title":"Ann. Neurol."},{"key":"427_CR156","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.bmt.1701010","volume":"20","author":"D Przepiorka","year":"1997","unstructured":"Przepiorka, D. et al. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transpl. 20, 983\u2013987 (1997).","journal-title":"Bone Marrow Transpl."},{"key":"427_CR157","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1701568","volume":"23","author":"D Re","year":"1999","unstructured":"Re, D. et al. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transpl. 23, 295\u2013298 (1999).","journal-title":"Bone Marrow Transpl."},{"key":"427_CR158","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00277-002-0481-4","volume":"81","author":"RJ Buckanovich","year":"2002","unstructured":"Buckanovich, R. J. et al. Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin\u2019s lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Ann. Hematol. 81, 410\u2013413 (2002).","journal-title":"Ann. Hematol."},{"key":"427_CR159","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1212\/01.wnl.0000183064.10227.b5","volume":"65","author":"L Kunschner","year":"2005","unstructured":"Kunschner, L. & Scott, T. F. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 65, 1510\u20131510 (2005).","journal-title":"Neurology"},{"key":"427_CR160","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/acn3.776","volume":"6","author":"D Stefoski","year":"2019","unstructured":"Stefoski, D. et al. Treatment of natalizumab-associated PML with filgrastim. Ann. Clin. Transl. Neurol. 6, 923\u2013931 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"427_CR161","doi-asserted-by":"publisher","unstructured":"Gasnault J., et al. Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. Open Forum Infect. Dis. https:\/\/doi.org\/10.1093\/ofid\/ofu074 (2014)","DOI":"10.1093\/ofid\/ofu074"},{"key":"427_CR162","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000213","volume":"3","author":"DP Miskin","year":"2016","unstructured":"Miskin, D. P. et al. Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia. Neurol. Neuroimmunol. Neuroinflamm. 3, e213 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"427_CR163","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13365-016-0465-0","volume":"23","author":"DN Soleimani-Meigooni","year":"2017","unstructured":"Soleimani-Meigooni, D. N. et al. JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. J. Neurovirol. 23, 141\u2013146 (2017).","journal-title":"J. Neurovirol."},{"key":"427_CR164","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s13365-018-0657-x","volume":"24","author":"A Harel","year":"2018","unstructured":"Harel, A. et al. Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia. J. Neurovirol. 24, 652\u2013655 (2018).","journal-title":"J. Neurovirol."},{"key":"427_CR165","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/jac\/dkq359","volume":"65","author":"A Patel","year":"2010","unstructured":"Patel, A., Patel, J. & Ikwuagwu, J. A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J. Antimicrob. Chemother. 65, 2697\u20132698 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"427_CR166","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciu682","volume":"59","author":"M Sospedra","year":"2014","unstructured":"Sospedra, M. et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin. Infect. Dis. 59, 1588\u20131592 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"427_CR167","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nri2970","volume":"11","author":"CL Mackall","year":"2011","unstructured":"Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11, 330\u2013342 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"427_CR168","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I Cortese","year":"2019","unstructured":"Cortese, I. et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 380, 1597\u20131605 (2019).","journal-title":"N. Engl. J. Med."},{"key":"427_CR169","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000627","volume":"6","author":"M Pawlitzki","year":"2019","unstructured":"Pawlitzki, M. et al. Ineffective treatment of PML with pembrolizumab: exhausted memory T-cell subsets as a clue? Neurol. Neuroimmunol. Neuroinflamm. 6, e627 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"427_CR170","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s10147-018-1259-6","volume":"23","author":"H Nagai","year":"2018","unstructured":"Nagai, H. & Muto, M. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int. J. Clin. Oncol. 23, 410\u2013420 (2018).","journal-title":"Int. J. Clin. Oncol."},{"key":"427_CR171","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/bmt.2010.221","volume":"46","author":"A Balduzzi","year":"2011","unstructured":"Balduzzi, A. et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transpl. 46, 987\u2013992 (2011).","journal-title":"Bone Marrow Transpl."},{"key":"427_CR172","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","volume":"379","author":"M Muftuoglu","year":"2018","unstructured":"Muftuoglu, M. et al. Allogeneic BK virus-specific T cells for progressive multifocal \u00f6eukoencephalopathy. N. Engl. J. Med. 379, 1443\u20131451 (2018).","journal-title":"N. Engl. J. Med."},{"key":"427_CR173","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02694783 (2020)"},{"key":"427_CR174","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-017-0669-2","volume":"17","author":"LP McLaughlin","year":"2017","unstructured":"McLaughlin, L. P., Bollard, C. M. & Keller, M. Adoptive T cell immunotherapy for patients with primary immunodeficiency disorders. Curr. Allergy Asthma Rep. 17, 3 (2017).","journal-title":"Curr. Allergy Asthma Rep."},{"key":"427_CR175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/cells8010047","volume":"8","author":"G Ottaviano","year":"2019","unstructured":"Ottaviano, G. et al. Adoptive T cell therapy strategies for viral infections in patients receiving haematopoietic stem cell transplantation. Cells. 8, 47 (2019).","journal-title":"Cells."},{"key":"427_CR176","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1212\/WNL.0b013e3182768983","volume":"79","author":"C Antoniol","year":"2012","unstructured":"Antoniol, C. et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 79, 2258\u20132264 (2012).","journal-title":"Neurology"},{"key":"427_CR177","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/01.wnl.0000343735.44983.5e","volume":"72","author":"JR Berger","year":"2009","unstructured":"Berger, J. R. Steroids for PML-IRIS: a double-edged sword? Neurology 72, 1454\u20131455 (2009).","journal-title":"Neurology"},{"key":"427_CR178","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1749-6632.2009.05111.x","volume":"1184","author":"T Johnson","year":"2010","unstructured":"Johnson, T. & Nath, A. Neurological complications of immune reconstitution in HIV-infected populations. Ann. NY Acad. Sci. 1184, 106\u2013120 (2010).","journal-title":"Ann. NY Acad. Sci."},{"key":"427_CR179","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1212\/WNL.0b013e3182768a21","volume":"79","author":"IJ Koralnik","year":"2012","unstructured":"Koralnik, I. J. & Clifford, D. B. Comment: avoiding detrimental effects of corticosteroids on JC virus T-cell responses\u2013primum non nocere. Neurology 79, 2263\u20132263 (2012).","journal-title":"Neurology"},{"key":"427_CR180","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1304828","volume":"370","author":"PS Giacomini","year":"2014","unstructured":"Giacomini, P. S. et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N. Engl. J. Med. 370, 486\u2013488 (2014).","journal-title":"N. Engl. J. Med."},{"key":"427_CR181","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000323","volume":"4","author":"G Bsteh","year":"2017","unstructured":"Bsteh, G. et al. Severe early natalizumab-associated PML in MS: effective control of PML-IRIS with maraviroc. Neurol. Neuroimmunol. Neuroinflamm. 4, e323 (2017).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"427_CR182","volume":"4","author":"SC Hodecker","year":"2017","unstructured":"Hodecker, S. C. et al. Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. Neurol. Neuroimmunol. Neuroinflamm. 4, e325 (2017).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"427_CR183","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jns.2017.05.018","volume":"378","author":"C Scarpazza","year":"2017","unstructured":"Scarpazza, C. et al. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy? J. Neurol. Sci. 378, 233\u2013237 (2017).","journal-title":"J. Neurol. Sci."},{"key":"427_CR184","doi-asserted-by":"crossref","first-page":"381480","DOI":"10.1155\/2014\/381480","volume":"2014","author":"M Rodr\u00edguez","year":"2014","unstructured":"Rodr\u00edguez, M. et al. Maraviroc failed to control progressive multifocal leukoencephalopathy-associated IRIS in a patient with advanced HIV infection. Case Rep. Med. 2014, 381480\u2013381483 (2014).","journal-title":"Case Rep. Med."},{"key":"427_CR185","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/jnnp.2009.179002","volume":"81","author":"MA Lima","year":"2010","unstructured":"Lima, M. A., Bernal-Cano, F., Clifford, D. B., Gandhi, R. T. & Koralnik, I. J. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J. Neurol. Neurosurg. Psychiatry 81, 1288\u20131291 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"427_CR186","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","volume":"76","author":"P Vermersch","year":"2011","unstructured":"Vermersch, P. et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76, 1697\u20131704 (2011).","journal-title":"Neurology"},{"key":"427_CR187","volume":"6","author":"P Anand","year":"2019","unstructured":"Anand, P., Hotan, G. C., Vogel, A., Venna, N. & Mateen, F. J. Progressive multifocal leukoencephalopathy: A 25-year retrospective cohort study. Neurol. Neuroimmunol. Neuroinflamm. 6, e618 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"427_CR188","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1002\/jcp.24051","volume":"227","author":"S Delbue","year":"2012","unstructured":"Delbue, S. et al. JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. J. Cell Physiol. 227, 3511\u20133517 (2012).","journal-title":"J. Cell Physiol."},{"key":"427_CR189","volume":"12","author":"R Schneider","year":"2017","unstructured":"Schneider, R. et al. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML). PLoS One 12, e0176415 (2017).","journal-title":"PLoS One"},{"key":"427_CR190","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/jnen\/62.5.429","volume":"62","author":"F Gray","year":"2003","unstructured":"Gray, F., Chr\u00e9tien, F., Vallat-Decouvelaere, A. V. & Scaravilli, F. The changing pattern of HIV neuropathology in the HAART era. J. Neuropathol. Exp. Neurol. 62, 429\u2013440 (2003).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"427_CR191","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF00307690","volume":"80","author":"M Schmidbauer","year":"1990","unstructured":"Schmidbauer, M., Budka, H. & Shah, K. V. Progressive multifocal leukoencephalopathy (PML) in AIDS and in the pre-AIDS era. A neuropathological comparison using immunocytochemistry and in situ DNA hybridization for virus detection. Acta Neuropathol. 80, 375\u2013380 (1990).","journal-title":"Acta Neuropathol."},{"key":"427_CR192","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000346","volume":"4","author":"E Maillart","year":"2017","unstructured":"Maillart, E. et al. Natalizumab-PML survivors with subsequent MS treatment: clinico-radiologic outcome. Neurol. Neuroimmunol. Neuroinflamm. 4, e346 (2017).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"427_CR193","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJMc1415408","volume":"372","author":"T Rosenkranz","year":"2015","unstructured":"Rosenkranz, T., Novas, M. & Terborg, C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N. Engl. J. Med. 372, 1476\u20131478 (2015).","journal-title":"N. Engl. J. Med."},{"key":"427_CR194","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-cases-rare-brain-infection-ms-drug-gilenya-fingolimod (2015)."},{"key":"427_CR195","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","volume":"60","author":"ES Molloy","year":"2009","unstructured":"Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 60, 3761\u20133765 (2009).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-00427-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-00427-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-00427-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:25:25Z","timestamp":1733937925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-00427-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":195,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1038\/s41582-020-00427-y","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"13 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}